AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36163415 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel without modification (n=167)
Number of subjects: 206
Study 36163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet modification based on PRU value
Number of subjects: 206
Study 36163415 — intervention group
Group type: EXPERIMENTAL
Intervention: PRU cutoff values
Number of subjects: 206
Study 36163427 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study 36163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Community member reviews
Number of subjects: 578
Study 36163530 — intervention group
Group type: COMPARATOR
Intervention: Scientific reviews
Number of subjects: 578
Study 36163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Community reviewer comments
Number of subjects: 578
Study 36163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Published intervention articles
Number of subjects: 578
Study 36163561 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-laparoscopic pancreaticoduodenectomy with stented pancreaticogastrostomy and Roux-en-Y gastroenterostomy
Number of subjects: 347
Study 36164254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin plus miltefosine (PM/MF) for 14 days
Number of subjects: 439
Study 36164254 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate plus paromomycin (SSG/PM) for 17 days
Number of subjects: 439
Study 36164334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin nanosuspension mucoadhesive nasal spray (two puffs per day)
Number of subjects: 96
Study 36164334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline nasal spray)
Number of subjects: 96
Study 36164334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin group
Number of subjects: 96
Study 36164334 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 96
Study 36164471 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Physical Functioning-10 items scale (PF-10) for OHCA survivors
Number of subjects: 287
Study 36164471 — intervention group
Group type: COMPARATOR
Intervention: Self-reported Physical Functioning-10 items scale (PF-10) for STEMI controls
Number of subjects: 287
Study 36164935 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg administered intravenously on day 1 of each 21-day cycle
Number of subjects: 51
Study 36164935 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 51
Study 36165038 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast/Ovarian cancer syndrome
Number of subjects: 799
Study 36165038 — intervention group
Group type: COMPARATOR
Intervention: Colorectal cancer
Number of subjects: 799
Study 36165055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (Pentasa) treatment
Number of subjects: 93
Study 36165137 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary UbA52 level in DM-NP group
Number of subjects: 90
Study 36165137 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary UbA52 level
Number of subjects: 90
Study 36165137 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria level
Number of subjects: 90
Study 36165137 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary UbA52
Number of subjects: 90
Study 36165742 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (with or without adjuncts)
Number of subjects: 6522
Study 36165893 — intervention group
Group type: EXPERIMENTAL
Intervention: FAK inhibition (defactinib) in combination with stereotactic body radiotherapy (RT)
Number of subjects: 0
Study 36165893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RT and FAK inhibition with checkpoint immunotherapy
Number of subjects: 0
Study 36165893 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study 36166279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 300
Study 36166279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 300
Study 36166279 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 300
Study 36166279 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture
Number of subjects: 300
Study 36166279 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 300
Study 36166287 — intervention group
Group type: EXPERIMENTAL
Intervention: Care ally-assisted massage (3.5-hour training workshop, instructional DVD, printed treatment manual, three 30-minute at-home sessions weekly for 3 months)
Number of subjects: 0
Study 36166287 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-treated massage (two 60-minute sessions tailored to individual pain experiences and treatments per week for 3 months)
Number of subjects: 0
Study 36166287 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 36166289 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based serious game (Jintronix system)
Number of subjects: 51
Study 36166289 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Graded Repetitive Arm Supplementary Program kit)
Number of subjects: 51
Study 36166340 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) with dual or triple antiplatelet therapy
Number of subjects: 1080
Study 36166340 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (warfarin) with corresponding strategies
Number of subjects: 1080
Study 36166340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy
Number of subjects: 1080
Study 36166340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Number of subjects: 1080
Study 36166648 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven digital health solution for self-management and clinical decision support
Number of subjects: 10
Study 36166648 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices and validated patient-reported outcomes questionnaires
Number of subjects: 10
Study 36166648 — intervention group
Group type: EXPERIMENTAL
Intervention: Publicly available health and lifestyle data registries
Number of subjects: 10
Study 36166658 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback group
Number of subjects: 46
Study 36166658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 36166849 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 163
Study 36166849 — intervention group
Group type: EXPERIMENTAL
Intervention: Females in obese group
Number of subjects: 163
Study 36167478 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional catheters
Number of subjects: 158
Study 36167478 — intervention group
Group type: COMPARATOR
Intervention: No regional analgesia
Number of subjects: 158
Study 36167501 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 36167557 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with teleconsultations, early warning system, and digital patient record system.
Number of subjects: 25
Study 36167557 — intervention group
Group type: COMPARATOR
Intervention: Standard care with telemedicine component.
Number of subjects: 25
Study 36167584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment.
Number of subjects: 180
Study 36167584 — intervention group
Group type: COMPARATOR
Intervention: Patients who refused to participate in the intervention.
Number of subjects: 180
Study 36167584 — intervention group
Group type: COMPARATOR
Intervention: Female sex as a factor associated with non-participation.
Number of subjects: 180
Study 36167584 — intervention group
Group type: COMPARATOR
Intervention: Time from diabetes diagnosis as a factor associated with non-participation.
Number of subjects: 180
Study 36167584 — intervention group
Group type: COMPARATOR
Intervention: Age comparison between participants and non-participants.
Number of subjects: 180
Study 36167584 — intervention group
Group type: COMPARATOR
Intervention: Time from diabetes diagnosis comparison between participants and non-participants.
Number of subjects: 180
Study 36167789 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-15 intermittent fitness test
Number of subjects: 0
Study 36167894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC) with median dosage of 17.6 g/m (IQR 16.5-18.0)
Number of subjects: 642
Study 36167894 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose cytarabine (IDAC)
Number of subjects: 642
Study 36168113 — intervention group
Group type: EXPERIMENTAL
Intervention: HALT patients
Number of subjects: 153
Study 36168113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' cognitive trajectory
Number of subjects: 153
Study 36168113 — intervention group
Group type: EXPERIMENTAL
Intervention: HALT and WMH burden
Number of subjects: 153
Study 36168454 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual clinician feedback
Number of subjects: 26
Study 36168454 — intervention group
Group type: COMPARATOR
Intervention: Clinic-level feedback
Number of subjects: 26
Study 36168552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with thrombotic complications
Number of subjects: 904
Study 36168552 — intervention group
Group type: COMPARATOR
Intervention: Patients without thrombotic complications
Number of subjects: 904
Study 36168857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - performed strengthening, stretching, and aerobic exercises for 30 minutes, 5 days a week.
Number of subjects: 49
Study 36168857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Counselling Indications (RCI) - followed by both groups, 7 days a week.
Number of subjects: 49
Study 36168857 — intervention group
Group type: COMPARATOR
Intervention: Control Group - Counselling Group (CG)
Number of subjects: 49
Study 36168949 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during EVAR procedures
Number of subjects: 22
Study 36168949 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during PVI procedures
Number of subjects: 22
Study 36168949 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during procedures
Number of subjects: 22
Study 36169967 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Number of subjects: 0
Study 36169967 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36169998 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD360 platform with serious game 'Pizza on Time' for approximately 30-45 minutes followed by 2-week behavior monitoring and 10 weeks of gameplay (2 times per week)
Number of subjects: 43
Study 36169998 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior monitoring through the mADHD360 app after initial evaluation
Number of subjects: 43
Study 36169998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gameplay data analysis using state-of-the-art ML algorithms
Number of subjects: 43
Study 36169998 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial neuropsychological evaluation
Number of subjects: 43
Study 36170017 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensified treatment
Number of subjects: 0
Study 36170017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Social mapping exercise indicating strength and direction of influence of members in their social networks.
Number of subjects: 33
Study 36170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Community- and peer-based PrEP sensitization and delivery interventions.
Number of subjects: 33
Study 36170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support for PrEP use.
Number of subjects: 33
Study 36170256 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage-PD telehealth coaching program
Number of subjects: 62
Study 36170336 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalization
Number of subjects: 104590
Study 36170501 — intervention group
Group type: EXPERIMENTAL
Intervention: GPRC5D-targeted CAR T-cell therapy (MCARH109) at a maximum tolerated dose of 150×10^6 cells.
Number of subjects: 17
Study 36170808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype C (ischemic phenotype)
Number of subjects: 122
Study 36170808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype B (edema phenotype)
Number of subjects: 122
Study 36170808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phenotypes B and C
Number of subjects: 122
Study 36170808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype B
Number of subjects: 122
Study 36170815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) cycles
Number of subjects: 0
Study 36170815 — intervention group
Group type: EXPERIMENTAL
Intervention: NADPH oxidase inhibitor apocynin
Number of subjects: 0
Study 36170815 — intervention group
Group type: COMPARATOR
Intervention: Protein restriction cycles
Number of subjects: 0
Study 36170815 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD cycles in a small group of AD patients
Number of subjects: 0
Study 36171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative subscales of the Self-Compassion Scale (SCS) and daytime sleepiness
Number of subjects: 467
Study 36171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 467
Study 36171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions focused on reducing negative self-compassion and improving sleep behavior
Number of subjects: 467
Study 36171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing diabetes-related distress (DRD)
Number of subjects: 467
Study 36171082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postinfective bowel dysfunction (PI-BD)
Number of subjects: 155
Study 36171082 — intervention group
Group type: COMPARATOR
Intervention: High fibre diets (prebiotic effect)
Number of subjects: 155
Study 36171082 — intervention group
Group type: COMPARATOR
Intervention: Age-matched and sex-matched controls
Number of subjects: 155
Study 36171104 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal Expanded Disability Status Scale (EDSS) scores modeled by latent class growth analysis (LCGA)
Number of subjects: 3613
Study 36171475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mutant virus (A(H1N1)pdm09 with NA-H275Y and PA-I38T mutations)
Number of subjects: 0
Study 36171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SVCF < 55 ml/kg/min
Number of subjects: 132
Study 36171508 — intervention group
Group type: EXPERIMENTAL
Intervention: High ACA-RI > 0.75
Number of subjects: 132
Study 36171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of low SVCF < 55 ml/kg/min and ACA-RI > 0.75
Number of subjects: 132
Study 36171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SVCF and high ACA-RI
Number of subjects: 132
Study 36171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metrics using cut-off value of < 41 ml/kg/min for SVCF and > 0.85 for ACA-RI
Number of subjects: 132
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: BATT score (prehospital)
Number of subjects: 13222
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC score (prehospital)
Number of subjects: 13222
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Index (SI) (prehospital)
Number of subjects: 13222
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: TASH score (at hospital admission)
Number of subjects: 13222
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: BATT score
Number of subjects: 13222
Study 36171598 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive transfusion (MT)
Number of subjects: 13222
Study 36171964 — intervention group
Group type: EXPERIMENTAL
Intervention: Khanya intervention (Life Steps adherence counseling, motivational interviewing, behavioral activation, and relapse prevention including mindfulness-based relapse prevention)
Number of subjects: 0
Study 36171964 — intervention group
Group type: EXPERIMENTAL
Intervention: Khanya intervention
Number of subjects: 0
Study 36171985 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Hi, Mcat, or HRV in sputum samples during exacerbation episodes
Number of subjects: 197
Study 36171985 — intervention group
Group type: COMPARATOR
Intervention: Sputum samples collected during stable COPD and AECOPD
Number of subjects: 197
Study 36171985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean yearly AECOPD incidence rate
Number of subjects: 197
Study 36172030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with alteplase
Number of subjects: 0
Study 36172030 — intervention group
Group type: COMPARATOR
Intervention: Baseline systolic blood pressure (trichotomized as high (141-185 mmHg), middle (121-140 mmHg), and low (91-120 mmHg))
Number of subjects: 0
Study 36172135 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 2247
Study 36172135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247
Study 36172135 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 and Placebo
Number of subjects: 2247
Study 36172138 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (single dose infusion)
Number of subjects: 1033
Study 36172138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033
Study 36172173 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib maintenance
Number of subjects: 3
Study 36172517 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish quality register for systematic data collection from patients receiving treatment for gambling disorder.
Number of subjects: 0
Study 36172517 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality register data collection
Number of subjects: 0
Study 36172535 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 317
Study 36172535 — intervention group
Group type: COMPARATOR
Intervention: No Physiotherapy
Number of subjects: 317
Study 36172577 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 36172577 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with complete revascularization (PCI-CR)
Number of subjects: 0
Study 36172577 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with incomplete revascularization (PCI-IR)
Number of subjects: 0
Study 36172577 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 36172964 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone prescription in ideal patients
Number of subjects: 2122
Study 36172964 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone prescription in contraindicated patients
Number of subjects: 2122
Study 36173242 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiSmart epi-on crosslinking (riboflavin/sodium iodide and pulsed UVA exposure)
Number of subjects: 2228
Study 36173261 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) consisting of 3 sets of 10 repetitions at 60% of 1 repetition maximum (1RM)
Number of subjects: 20
Study 36173261 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 20
Study 36173399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade testing in FH families with a monogenic etiology
Number of subjects: 52
Study 36173399 — intervention group
Group type: COMPARATOR
Intervention: Cascade testing in FH families without a monogenic etiology
Number of subjects: 52
Study 36173816 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score)
Number of subjects: 207
Study 36173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score) among European Americans
Number of subjects: 207
Study 36173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (5 points lower E-DII score)
Number of subjects: 207
Study 36174113 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole/Abemaciclib
Number of subjects: 30
Study 36174135 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 0
Study 36174389 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive finger blood pressure (BP)
Number of subjects: 33
Study 36174613 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-arterial (VA)-ECMO
Number of subjects: 391
Study 36174613 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous (VV)-ECMO
Number of subjects: 391
Study 36174613 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 391
Study 36174613 — intervention group
Group type: COMPARATOR
Intervention: VV-ECMO
Number of subjects: 391
Study 36174613 — intervention group
Group type: COMPARATOR
Intervention: VA-ECMO
Number of subjects: 391
Study 36174774 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 36174774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 36174774 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 36175036 — intervention group
Group type: EXPERIMENTAL
Intervention: lerapolturev
Number of subjects: 12
Study 36175060 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided greater splanchnic nerve (GSN) ablation
Number of subjects: 11
Study 36175098 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute management interventions including protective equipment and decontamination capabilities
Number of subjects: 0
Study 36175253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight (<60 kg)
Number of subjects: 11821
Study 36175253 — intervention group
Group type: EXPERIMENTAL
Intervention: High body weight (>100 kg)
Number of subjects: 11821
Study 36175253 — intervention group
Group type: COMPARATOR
Intervention: Middle body weight (60 to 100 kg)
Number of subjects: 11821